Allen Lapey

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: January 18, 2016

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.

Journal: The Lancet. Respiratory medicine

Published: November 09, 2015

Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: December 06, 2014

Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: June 24, 2014

Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis.

Journal: The Journal of clinical endocrinology and metabolism

Published: June 14, 2014

Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis.

Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis.

Human Airway Basal Cells Undergo Reversible Squamous Differentiation and Reshape Innate Immunity.

Human Airway Basal Cells Undergo Reversible Squamous Differentiation and Reshape Innate Immunity.

Working towards consensus in the management of pediatric chronic rhinosinusitis in cystic fibrosis.

Working towards consensus in the management of pediatric chronic rhinosinusitis in cystic fibrosis.

SMAD Signaling Restricts Mucous Cell Differentiation in Human Airway Epithelium.

SMAD Signaling Restricts Mucous Cell Differentiation in Human Airway Epithelium.

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

Effects of a primary palliative care intervention on quality of life and mental health in cystic fibrosis.

Effects of a primary palliative care intervention on quality of life and mental health in cystic fibrosis.

Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells.

Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells.

Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis.

Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis.

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.

Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers.

Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers.

Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period.

Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period.

Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis.

Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis.

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).